Product Reports Resources Pricing Login Book a demo
COMPANY PROFILE

Edgewood Oncology

Request full access

We look forward to further developing this compound using a precision medicine approach in patient populations who lack effective treatment options

Brookline, United StatesFounded 2023Biotech & Life Sciences

About Edgewood Oncology

Edgewood Oncology is a clinical-stage biotechnology company focused on advancing BTX A51, a novel small molecule, multi-kinase inhibitor. The company targets hematologic malignancies and genetically defined solid tumors, including GATA3 mutant breast cancer. Edgewood Oncology operates in the precision medicine market, aiming to provide effective treatment options for patients with significant unmet medical needs. The business model revolves around developing and commercializing BTX A51 through clinical trials and partnerships. Revenue is generated through funding rounds, such as the recent $20 million Series A financing, and future commercialization of their therapies.

Source: Dealroom company data

At a glance

Status
Operational
Employees
2
Open positions
None listed
Dealroom signal
55.2/100
Industry
Health
Sub-industry
BioTechnology
Sector
Biotechnology, Precision Medicine, Spinout, Biotech and Pharma, DT and LS, science-based
Business model
Manufacturing
Client focus
B2B

Funding history

2 recorded events

Company financing events and reported valuations.

Deal typeDateAmountValuationInvestorsSource
SERIES A✓Equity / VC Mar 2024 $20M $80M Alta Partners ↗
SPINOUT✓Other financing Jan 2023 $0 — Yissum Research Development · The Hebrew University of Jerusalem —
Showing the latest 2 of 2 recorded eventsBook a demo for the full funding history →

Growth signals

Edgewood Oncology website traffic

Latest recorded traffic for Edgewood Oncology is 1.5K monthly website visits, up 158.6% over the last three months. Edgewood Oncology's team grew 0% over the past year.

Latest monthly visits1.5K 3-month web change+158.6% 1-year team growth0%
Summary metrics are public; monthly history is available with a demoCompare with peers →

Investments and acquisitions

Capital deployed

Recent portfolio relationships for companies that also act as investors or acquirers.

Edgewood Oncology in the Brookline ecosystem

Live from Dealroom

The Edgewood Oncology office with the hot startups, most funded companies and investors around it. Hover or tap a pin.

Loading the map…

Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →

Investors

3 investors on the cap table

From Dealroom's funding and investor records, grouped by the round each investor first entered.

Series A1 investor entered at this stage

  • Alta Partners

Other known investors2 additional known investors

  • The Hebrew University of Jerusalem
  • Yissum Research Development
Team profiled 2 named & role-tagged
Founders Hidden — book a demo/100 quality score
Key operators 2 quality Hidden — book a demo/100
Potential founders Hidden — book a demo likely future founders
Startup mafia Hidden — book a demo alumni-founded startups
Talent movements Hidden — book a demo in · Hidden — book a demo out past 12 months

Source: Dealroom Talent Intelligence.

Global footprint

Workforce and web traffic by country
Workforce by country
1 countries with
team presence
🇺🇸 United States100%
1 country shown

Market sentiment

Posts on X, past 7 days

An AI-synthesised read of the highest-engagement posts about Edgewood Oncology on X, ranked by likes and reposts, corporate channels excluded.

Reading the room on X — pulling top posts and synthesizing themes…

Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour

See Edgewood Oncology’s full profile on Dealroom

Request a free trial to see the complete deal history, financials, people graph and growth signals.

Takes under a minute. Already use Dealroom? Log in.